CTRV - ContraVir Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 55.88M
Enterprise Value 34.82M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)N/A
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-0.38

Trading Information

Stock Price History

Beta (3Y Monthly) -0.12
52-Week Change 3-94.66%
S&P500 52-Week Change 36.34%
52 Week High 364.4000
52 Week Low 33.5200
50-Day Moving Average 35.2279
200-Day Moving Average 313.4236

Share Statistics

Avg Vol (3 month) 3824.91k
Avg Vol (10 day) 3181.45k
Shares Outstanding 585.45M
Float 176.01k
% Held by Insiders 136.42%
% Held by Institutions 13.72%
Shares Short (Jun 28, 2019) 452.38k
Short Ratio (Jun 28, 2019) 40.03
Short % of Float (Jun 28, 2019) 421.51%
Short % of Shares Outstanding (Jun 28, 2019) 43.19%
Shares Short (prior month May 31, 2019) 46.56k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 270/1
Last Split Date 3Jun 3, 2019

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019


Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-91.43%
Return on Equity (ttm)-472.93%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -12.64M
Net Income Avi to Common (ttm)-17.22M
Diluted EPS (ttm)-81.8950
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)1.68M
Total Cash Per Share (mrq)2.85
Total Debt (mrq)2.64M
Total Debt/Equity (mrq)408.43
Current Ratio (mrq)0.55
Book Value Per Share (mrq)-3.77

Cash Flow Statement

Operating Cash Flow (ttm)-14.11M
Levered Free Cash Flow (ttm)-9.38M